An Update on Reversal of Atherosclerosis at Repair Biotechnologies

As some of you know, Repair Biotechnologies is the company I co-founded with Bill Cherman back in 2018. We've been working on an approach to reverse atherosclerosis for much of that time, and matters have progressed through the stage of great data in mice to present preparations for a pre-IND meeting with the FDA. While excess cholesterol has long been understood to be important to the development of atherosclerosis, it turns out that circulating cholesterol bound to LDL particles is less important than the amount of localized excess cholesterol in the liver and blood vessel walls.

Any localized excess of cholesterol can overwhelm the ability of cells to reduce uptake or store cholesterol in either the cell membrane or in esterified droplets. The resulting free cholesterol inside cells is toxic. The gene therapies developed by the Repair Biotechnologies scientists put in place novel protein machinery that can selectively and safely break down this excess free cholesterol without harming the cholesterol necessary to cell function. This can, for example, protect macrophages from becoming foam cells when exposed to excessive cholesterol. It can also put a halt to dysfunction in liver cells affected by the excess cholesterol present in a fatty liver.

Repair Biotechnologies' gene therapy rapidly reverses atherosclerosis in mice

Gene therapy company Repair Biotechnologies has revealed promising preclinical results that demonstrate its technology rapidly reverses the progression of atherosclerosis in mouse models. The company says the development holds potential for treating both atherosclerosis and a rare genetic condition called familial hypercholesterolemia, in humans.

Atherosclerosis is a condition characterized by the buildup of plaque in arteries, eventually blocking blood flow, and contributing significantly to heart disease, stroke, and death. In experiments, scientists at Repair Biotechnologies treated atherosclerotic mouse models with the lipid nanoparticle (LNP)-messenger RNA (mRNA) therapy over a six-week period, with promising results.

Both groups of mice, one representing a general population model for atherosclerosis, and another modeling familial hypercholesterolemia, exhibited significant reductions in plaque buildup. Specifically, the atherosclerotic mice showed a 19% drop in plaque lipids and a 23% increase in plaque collagen, indicating stabilization of vulnerable plaque. The mice with familial hypercholesterolemia experienced a 17% reduction in plaque obstruction in the aortic root, alongside improved cardiovascular health demonstrated by increased treadmill capacity.

Based in Syracuse, New York, Repair Bio is developing LNP-mRNA therapies targeting a range of health conditions. Unlike traditional therapies that focus on reducing LDL-cholesterol levels in the bloodstream, the company's therapy targets intracellular free cholesterol, which is toxic to cells and contributes to the development of numerous conditions. Repair Bio's approach leverages its cholesterol degrading platform technology to safely break down excess free cholesterol within cells.

"Unfortunately statins and PCSK9 inhibitors that reduce LDL-cholesterol in the blood exhibit little ability to reduce the size of established atherosclerotic lesions," said Mourad Topors, CSO at Repair Bio. "Our studies in severely atherosclerotic mice demonstrate that LDL-cholesterol is the wrong target if the goal is the outright regression of plaque and dramatic reduction in risk of cardiovascular events. Instead, clearance of intracellular free cholesterol can potentially achieve these goals."


Reason, have you considered trying to get funding for your company through a venture capital site like Wefunder? Some of the companies are getting a few million dollars that way and I feel like there is pent up demand for this because to my knowledge no other life extension company has tried this, I would put at least 10k in myself. It might also be another way of raising awareness for this field.

Posted by: Corbin at April 11th, 2024 2:06 PM

congrats!! Looking forward to more good news

Posted by: Gregory Schulte at April 11th, 2024 6:28 PM

Wow, I am extremely impressed, Reason. I hugely hope you can FastTrack this treatment, if successful, and save many people.

Then, I hope you and Bill make alot from it.

Then, I hope you attack another medical issue, maybe dementia, seems the researchers needs some fresh eyes on the problem.

Anyways, congratulations for getting this far, imo, quickly. Please keep us posted with your progress.

Posted by: Robert at April 11th, 2024 10:23 PM

I like the modern site and the graphs in colors that shows statins, PCS9, gene therapy. Also like logo and the ''pacman''.

Posted by: Renata at April 12th, 2024 1:48 AM

Im extremely curious and waiting for the undisclosed liver indication. Could it be something Alcohol Use Disorder (AUD) related?

Posted by: Ara at April 12th, 2024 1:56 AM

Thanks so much for doing this. You guys (& girls) are heroes.

I hope you make loads of money, then reinvest a bit in mRNA therapy for catabolic antibodies for Alzheimer's protein aggregates in the brain.

Posted by: jimofoz at April 12th, 2024 5:34 AM

Good to hear about the progress to clinical trials!

Posted by: Antonio at April 12th, 2024 3:48 PM
Comment Submission

Post a comment; thoughtful, considered opinions are valued. New comments can be edited for a few minutes following submission. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.